← Back
Data updated: Mar 10, 2026
EISAI MEDCL RES
Infectious DiseaseGastroenterology
EISAI MEDCL RES is a pharmaceutical company focused on Infectious Disease, Gastroenterology.
2002
Since
1
Drugs
-
Trials
0
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
No recent activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 50%
1 drugs
Gastroenterology 50%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Gastroenterology, Infectious Disease
APOTHECON specialty
Infectious Disease, Gastroenterology
Gilead Sciences biotech
Infectious Disease, Gastroenterology
WAYLIS THERAP big-pharma
Infectious Disease, Gastroenterology
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2002-11-08
- Latest
- 2002-11-08
- Applications
- 1